Clinical and endocrinological effects of letrozole during the luteal phase after controlled ovarian stimulation in oocyte donors: a low interventional, randomized, controlled trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502586-21-00

Acronym

2206-MAD-089-SC

Enrollment

152

Registered

2023-03-17

Start date

2023-12-04

Completion date

2025-06-02

Last updated

2024-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility

Brief summary

ovarian volume

Detailed description

Plasma values of VEGF, sFlt-1, oestradiol, progesterone, FSH, LH and testosterone

Interventions

DRUGLETROZOLE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
ovarian volume	—

Secondary

Measure	Time frame
Plasma values of VEGF, sFlt-1, oestradiol, progesterone, FSH, LH and testosterone	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026